

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
14/YH/1269	140294	A Phase 3, OpenLabel, Randomised, Parallel, 2Arm, MultiCenter Study of BMN 673 versus Physician's Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received No More than 2 Prior Chemotherapy Reg	Range Agreed	1	2	Not Available / Not Agreed			20/04/2017	2	Recruitment Finished
14/YH/0088	151005	Phase I study of KHK2823 in Patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome	Range Agreed	4	8	Date Agreed	01/02/2017	4	30/06/2017	4	Recruitment Finished
15/NW/0543	181870	A Multicentre, Randomised, Doubleblind, Placebo controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus	Range Agreed	2	3	Date Agreed	30/04/2017	0	30/06/2017	0	Recruitment Finished
16/LO/0586	200579	An Open-Label Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients with Relapsing Remitting Multiple Sclerosis who have a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment	Number Agreed	4	4	Date Agreed	31/07/2017	0	03/03/2017	0	Recruitment Finished
15/YH/0478	186697	A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis	Range Agreed	5	10	Date Agreed	31/10/2016	0	18/08/2017	0	Withdrawn By Host
16/EM/0386	211113	A 12-week double-blind, randomized, multicenter study comparing the efficacy and safety of once monthly subcutaneous 140 mg AMG 334 against placebo in adult episodic migAraine patients who have failed 2-4 prophylactic treatments	Number Agreed	4	4	Date Agreed	22/08/2016	2	03/05/2017	2	Recruitment Finished
16/LO/0265	187356	Profiling of Serum HbsAg Levels and Hepatitis B Virus-Specific T-Cell Responses in Chronic Hepatitis B Patients under Antiviral Treatment	Range Agreed	40	70	Date Agreed	31/03/2016	3	19/06/2017	3	Withdrawn By Sponsor
17/EM/0143	219212	An evaluation of the current treatment pathways and associated NHS resource use for the management of uncontrolled moderate-to-severe atopic dermatitis in secondary care	Range Agreed	1	8	Date Agreed	30/09/2017	12	27/09/2017	12	Recruitment Finished
16/EE/0463	214371	CLEE011A2404. Ribociclib and Letrozole in HR+, HER-breast cancer	Range Agreed	5	7	Date Agreed	31/12/2019	7	27/09/2017	7	Recruitment Finished
13/LO/0572	121866	Phase III of Two Single tablet regimens in HIV1 Positive Adults	Number Agreed	10	10	Not Available / Not Agreed			29/09/2017	1	Recruitment Finished
16/LO/2128	216431	Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes in Patients with Locally Advanced or Metastatic NSCLC	Range Agreed	10	40	Date Agreed	28/02/2019	2	08/11/2017	2	Withdrawn By Sponsor